Clinical trial

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity

NCT06315972

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2024-04-01

PhasePHASE2

Study timeline

Study start (estimated)2024-04-01Date precision: month

Registry last updated2024-03-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

clemastine (8 mg/day)DRUG

PlaceboDRUG

Sponsors & collaborators

LMU Klinikumlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06315972 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.